Moreover, novel agents that blocks BCR signaling have been investigated in relapsed patients with MCL such as Syk inhibitor (fostamatinib) [34] and PI3Kδ inhibitor (idelalisib) [35]. This evidence concerns the gene BCR and mantle cell lymphoma.